Department of Pediatric Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Division of Pediatric Oncology, Shanghai Institute of Pediatric Research, Shanghai, China.
Pediatr Blood Cancer. 2018 Sep;65(9):e27229. doi: 10.1002/pbc.27229. Epub 2018 May 24.
Neuroblastoma is one of the most common pediatric solid tumors. Although the 5-year overall survival rate has increased over the past few decades, high-risk patients still have a poor prognosis due to a lack of biomonitoring therapy. This study was performed to investigate the role of Galectin-1 in neuroblastoma biomonitoring therapy.
A tissue microarray containing 37 neuroblastoma tissue samples was used to evaluate the correlation between Galectin-1 expression and clinical features. Blood samples were examined to better understand whether serum Galectin-1 (sGalectin-1) could be used for biomonitoring therapy. Kaplan-Meier analysis and ROC analysis was conducted to distinguish the outcome associated with high or low expression of Galectin-1 in patients with neuroblastoma.
Increased Galectin-1 expression was found in neuroblastoma and it was further demonstrated that elevated tissue Galectin-1 expression was related to INSS stage, histology, bone marrow metastasis, and poor survival. sGalectin-1 levels were higher in newly diagnosed patients with neuroblastoma than healthy subjects. Patients with elevated sGalectin-1 through treatment cycles correlated with the poor chemo-responses and tended to have worse outcomes, such as metastasis or stable tumor size, whereas gradually decreasing sGalectin-1 levels correlated with no observed progression in clinical symptoms.
Tissue and serum Galectin-1 levels were associated with adverse clinical features in patients with neuroblastoma, and sGalectin-1 could be a potential biomarker for monitoring therapy.
神经母细胞瘤是最常见的儿童实体瘤之一。尽管在过去几十年中，5 年总生存率有所提高，但由于缺乏生物监测治疗，高危患者的预后仍然较差。本研究旨在探讨半乳糖凝集素-1 在神经母细胞瘤生物监测治疗中的作用。
使用包含 37 个神经母细胞瘤组织样本的组织微阵列评估 Galectin-1 表达与临床特征之间的相关性。检查血液样本，以更好地了解血清 Galectin-1（sGalectin-1）是否可用于生物监测治疗。进行 Kaplan-Meier 分析和 ROC 分析，以区分神经母细胞瘤患者中 Galectin-1 高表达或低表达与预后的关系。
发现神经母细胞瘤中 Galectin-1 表达增加，并进一步表明组织 Galectin-1 表达升高与 INSS 分期、组织学、骨髓转移和不良生存相关。与健康受试者相比，新诊断的神经母细胞瘤患者的 sGalectin-1 水平更高。治疗周期中 sGalectin-1 升高的患者与化疗反应不良相关，且往往有更差的结局，如转移或肿瘤大小稳定，而 sGalectin-1 水平逐渐下降与临床症状无进展相关。
神经母细胞瘤患者的组织和血清 Galectin-1 水平与不良临床特征相关，sGalectin-1 可能是监测治疗的潜在生物标志物。
